We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Promoting Transparency in Pharmaceutical Industry-Sponsored Research.
- Authors
Ross, Joseph S.; Gross, Cary P.; Krumholz, Harlan M.
- Abstract
Strong, evidence-based practice requires that objective, unbiased research be available to inform individual clinical decisions, systematic reviews, meta-analyses, and expert guideline recommendations. Industry has used seeding trials, publication planning, messaging, ghostwriting, and selective publication and reporting of trial outcomes to distort the medical literature and undermine clinical trial research by obscuring information relevant to patients and physicians. Policies that promote transparency in the clinical trial research process, through improved and expanded disclosure of investigator contributions and funding, comprehensive publicly available trial registration, and independent analysis of clinical trial data analysis may address these subversive practices by improving accountability among industry and investigators. Minimizing marketing's impact on clinical trial research and strengthening the science will protect medical literature's integrity and the public's health.
- Subjects
UNITED States; EVALUATION of clinical trials; CLINICAL trial laws; MARKETING; AUTHORSHIP; CONFLICT of interests; ENDOWMENTS; PHARMACEUTICAL industry; PRODUCT safety; PUBLIC relations; PUBLISHING; RESEARCH evaluation; RESPONSIBILITY; SCIENTISTS; DECISION making in clinical medicine; DISCLOSURE; ACCESS to information; RESEARCH bias
- Publication
American Journal of Public Health, 2012, Vol 102, Issue 1, p72
- ISSN
0090-0036
- Publication type
Article
- DOI
10.2105/AJPH.2011.300187